

New York State Correctional Officers & Police Benevolent Association

102 Hackett Boulevard - Albany, NY 12209 (518) 427-1551 www.nyscopba.org nyscopba@usa.net



TO: NYSCOPBA Chief Sector Stewards

FROM: Sharon Smith, Health Benefits Specialist

DATE: May 28, 2020

RE: Empire Plan Voluntary Recall and New Updates

We have been notified of the following changes to the Empire Plan formulary.

There has been a voluntary recall of several lots of NP Thyroid. Apparently, these lots are too potent, as described in the notice on the "What's New" page of NYSHIP Online. The notice gives the dosages, lot numbers and expiration dates for the recalled medication. It also directs utilizers to contact their providers to discuss their next steps. CVS is sending out notices to all affected members and retirees using this medication (a total of 26 NYSCOPBA members and 89 planwide retirees).

In addition to the above, there will be some updates to the Empire Plan formulary effective 7/1/20.

A number of new generic medications will be added to Level I of the formulary and their brand-name equivalents will move from Level II to Level III, as required by plan rules. Below is a list of the new generics and their brand-name equivalents:

hydrocodone ext-rel (generic ZOHYDRO ER) QL/PA
posaconazole delayed-rel tablet (generic NOXAFIL)
pentamidine (generic NEBUPENT)
isosorbide dinitrate (generic ISORDIL 40mg)
doxepin (generic SILENOR)
cinacalcet (generic SENSIPAR)
ethinyl estradiol-etonorgestrel (generic NUVARING)
diazoxide (generic PROGLYCEM)
mesalamine ext-rel (generic APRISO)
budesonide-formoterol (generic SYMBICORT)

naftifine cream 2%, gel 1% (generic NAFTIN) ivermectin (generic SOOLANTRA) moxifloxacin (generic MOXEZA, VIGAMOX) travoprost (generic TRAVATAN Z)

There are also eight drugs that will be removed from the formulary because they have been discontinued by the manufacturers. They are: eprosartan, isosorbide dinitrate ext-rel, ranitidine, Eurax Cream, Eurax Lotion, Khedezia, Pataday and Patanol.

Finally, there are six recently FDA approved, new to the market, oncology drugs being added to the Specialty Drug List: Enhertu, Padcev, Ruxience, Sarclisa, Trazimera and Zirabev.

Should a member come to you in regard to any of the above, have them call the Empire Plan, (877)769-7447, Option 4 (the Prescription Drug Program), for assistance.

SS

cc: NYSCOPBA Executive Board NYSCOPBA Jt. Committee on Health Benefits